Loading…

Computational screening of chalcones acting against topoisomerase IIα and their cytotoxicity towards cancer cell lines

Targeted cancer therapy has become one of the high potential cancer treatments. Human topoisomerase II (hTopoII), which catalyzes the cleavage and rejoining of double-stranded DNA, is an important molecular target for the development of novel cancer therapeutics. In order to diversify the pharmacolo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2019-01, Vol.34 (1), p.134-143
Main Authors: Sangpheak, Kanyani, Mueller, Monika, Darai, Nitchakan, Wolschann, Peter, Suwattanasophon, Chonticha, Ruga, Ritbey, Chavasiri, Warinthon, Seetaha, Supaporn, Choowongkomon, Kiattawee, Kungwan, Nawee, Rungnim, Chompoonut, Rungrotmongkol, Thanyada
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted cancer therapy has become one of the high potential cancer treatments. Human topoisomerase II (hTopoII), which catalyzes the cleavage and rejoining of double-stranded DNA, is an important molecular target for the development of novel cancer therapeutics. In order to diversify the pharmacological activity of chalcones and to extend the scaffold of topoisomerase inhibitors, a series of chalcones was screened against hTopoIIα by computational techniques, and subsequently tested for their in vitro cytotoxicity. From the experimental IC 50 values, chalcone 3d showed a high cytotoxicity with IC 50 values of 10.8, 3.2 and 21.1 µM against the HT-1376, HeLa and MCF-7 cancer-derived cell lines, respectively, and also exhibited an inhibitory activity against hTopoIIα-ATPase that was better than the known inhibitor, salvicine. The observed ligand-protein interactions from a molecular dynamics study affirmed that 3d strongly interacts with the ATP-binding pocket residues. Altogether, the newly synthesised chalcone 3d has a high potential to serve as a lead compound for topoisomerase inhibitors.
ISSN:1475-6366
1475-6374
DOI:10.1080/14756366.2018.1507029